Share price of Immunomedics (NASDAQ:IMMU) Inc. IMMU has surged 77.4% year to date compared with the industry’s growth of 11%. It has been an eventful year so far for the company.
The company got a significant boost in April 2020 with the FDA approval for its lead drug, Trodelvy, (sacituzumabgovitecan-hziy), an antibody-drug conjugate (ADC), for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who received at least two prior therapies for metastatic disease. Following the nod, Trodelvy became the first ADC to receive an FDA approval, specifically for the treatment of relapsed or refractory mTNBC, which is an aggressive type of breast cancer. It is also the first FDA-approved anti-Trop-2 ADC. This marks the approval of the first drug ofthe company and will boost its growth prospects. Shares got a boost with this approval.
The drug is also being evaluated for additional indications. The FDA recently granted a Fast Track designation to Trodelvy for the treatment of adult patients with locally-advanced or metastatic urothelial cancer (mUC).
Meanwhile, the ASCENT study on Trodelvy was halted due to compelling evidence of efficacy. The top-line data are expected around mid-2020.
Meanwhile, Immunomedics has collaborated with the Dana-Farber Cancer Institute to conduct two phase II studies to evaluate the safety and efficacy of combining Trodelvy with Merck’s MRK anti-programmed cell death protein 1 (PD-1) antibody, Keytruda (pembrolizumab), in patients with mTNBC and hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer (mBC).
The company has also entered two clinical collaborations. It collaborated with Roche RHHBY (OTC:RHHBY) to develop Trodelvy in the front-line setting of mTNBC in combination with the latter’s PD-L1 inhibitor, Tecentriq.
The company has a similar collaboration agreement with AstraZeneca (NYSE:AZN) AZN to investigate Trodelvy in combination with the latter’s checkpoint inhibitor, Imfinzi (durvalumab), in earlier lines of therapy for mTNBC, advanced UC and second-line metastatic NSCLC.
These collaborations are constant sources of funds for the company.
Zacks Rank
Immunomedics is currently a Zacks Rank #2 (Buy) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Roche Holding AG (OTC:RHHVF) (RHHBY): Free Stock Analysis Report
Merck Co., Inc. (MRK): Free Stock Analysis Report
Immunomedics, Inc. (IMMU): Free Stock Analysis Report
To read this article on Zacks.com click here.